Skip to content

About Rick Stanton

Join the quest to find the best testing & treatment options for Rick Stanton as part of the Prostate Cancer Lab

This patient-focused research effort is bringing together researchers, patients, scientists, bioinformaticians, and medical professionals to explore what is driving Rick Stanton’s prostate cancer and the best testing & treatment options to stop it.

To participate, click the button to apply. You will then be invited to the weekly chats and online discussion forum.

Professionally: Rick Stanton is a 66-year-old southern California based family man with a passion to help cancer patients in need. He believes an integrated understanding of patient state, genomic state, immune state and trajectory will help inform clinical therapy decisions.

He is an engineer / data scientist with experience in complex physical and biological signaling systems. He has experience in genomics, transcriptomics, cellular pathway signaling, and immune signaling. 17 years Amgen, 5 years JCVI / Human Longevity, 3 years ThermoFisher Scientific. Technologies: AI, machine/deep learning, AWS hosted secure web applications, scientific programming.

Personally: family man, loves life, dogs, hockey, skiing, music in general, and guitar specifically.

Aggressive Metastatic Prostate Cancer primarily driven by unfavorable CDK12 mutation leading to short duration of control by therapies outlined by NCCN guidelines. Currently on chemo (docetaxel)

Rick needs the Lab to understand integrated strategies for testing & treatment options that go beyond standard of care that can be considered by his medical oncologist team. He believes medical oncologists can consider personalized, molecularly informed treatment options based on an integrated understanding of genomic, immune, and patient state. In particular, transcriptomics, immune signaling, and spatial analyses to characterize immunosuppression are desired.

Weekly video chats will update participants on progress and specific questions that will help channel the research. An online discussion forum (via Slack) will enable asynchronous review of progress and opportunities for comments. A recorded version of the weekly updates will be posted shortly after for those who are unable to attend. Insights and recommendations will funnel into a global virtual “molecular tumor board” of leading prostate cancer research oncologists and other experts.

Continuous Feedback Loop: From the point of launch, the team should provide the first treatment recommendation within 2 months. After administration of the treatment, Brian will provide the team with weekly updates on his treatment. These updates will include all available response metrics and side effects. This information will be used to assess next treatment options and the cycle will continue.

We are engaging many people, representing multiple disciplines across institutions globally and bending the healthcare system to address the unique needs of one patient.

If you participate you should expect a culture of open participation, open data, and open results.

You will be welcome to join weekly  calls of 60 minutes on Wednesday at 9am PST and an online discussion forum via Discord.

For people who are unable to attend the weekly meetings, there will be notes distributed by email, video recordings, and video summaries.

If you have analytical tools, you are encouraged to apply them and share your analysis. If you have specialist knowledge, you may participate in smaller discussions or may be asked to be on the molecular tumor board.

Prostate cancer patients, pathologists, scientists, researchers, medical professionals, bioinformaticians, oncologists and advocates with intermediate to advanced experience who would like to help Brian are welcome to participate.

By participating in the Prostate Cancer Lab, you will have the opportunity to contribute to a cure for Rick and the other cancer patients who have hit a wall, network with top influencers in the digital health and innovation community, and participate in cutting edge data analysis and therapy recommendations.

Contact Brad Power at for process, administration or organization questions

Contact Rick Stanton at